Cargando…

Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood–brain barrier (BBB) has left the central nervous system (CNS)-related symptoms of LSDs largely impervi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonoda, Hiroyuki, Takahashi, Kenichi, Minami, Kohtaro, Hirato, Toru, Yamamoto, Tatsuyoshi, So, Sairei, Tanizawa, Kazunori, Schmidt, Mathias, Sato, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229961/ https://www.ncbi.nlm.nih.gov/pubmed/35745811 http://dx.doi.org/10.3390/pharmaceutics14061240

Ejemplares similares

Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid
por: Sato, Yuji, et al.
Publicado: (2022)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
por: Tomita, Kazuyoshi, et al.
Publicado: (2021)

Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses
por: Minami, Kohtaro, et al.
Publicado: (2022)

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018)

Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil
por: Giugliani, Roberto, et al.
Publicado: (2021)

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
por: de Castro, María José, et al.
Publicado: (2021)

A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II
por: Okuyama, Torayuki, et al.
Publicado: (2021)

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
por: Baydakova, Galina, et al.
Publicado: (2020)

Issues of COVID-19-related distance learning for children with neuronopathic mucopolysaccharidoses
por: Eisengart, Julie B., et al.
Publicado: (2021)

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
por: Okuyama, Torayuki, et al.
Publicado: (2019)

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
por: Yamamoto, Ryuji, et al.
Publicado: (2021)

Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses
por: Sato, Yuji, et al.
Publicado: (2020)

Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice
por: Morimoto, Hideto, et al.
Publicado: (2022)

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023)

Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice
por: Morimoto, Hideto, et al.
Publicado: (2021)

Difficulties Associated with Enzyme Replacement Therapy for Mucopolysaccharidoses
por: Yıldız, Yılmaz, et al.
Publicado: (2021)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt
por: Fateen, Ekram, et al.
Publicado: (2021)

Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans
por: Arunkumar, Nivethitha, et al.
Publicado: (2021)

ENT and mucopolysaccharidoses
por: Bianchi, Pier Marco, et al.
Publicado: (2018)

Diagnosis of Mucopolysaccharidoses
por: Kubaski, Francyne, et al.
Publicado: (2020)

Glaucoma in mucopolysaccharidoses
por: Kong, Weijing, et al.
Publicado: (2021)

Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
por: Parini, Rossella, et al.
Publicado: (2020)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Grant, Nathan
Publicado: (2020)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)

Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities
por: Suzuki, Yoshiyuki, et al.
Publicado: (2009)

The new frame for Mucopolysaccharidoses
por: Parini, Rossella, et al.
Publicado: (2018)

Anesthesiological risks in mucopolysaccharidoses
por: Moretto, Alessandra, et al.
Publicado: (2018)

Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2018)

Orthopaedic challenges for mucopolysaccharidoses
por: Borgo, Andrea, et al.
Publicado: (2018)

Pathogenesis of Mucopolysaccharidoses, an Update
por: Fecarotta, Simona, et al.
Publicado: (2020)

Ophthalmological Findings in Mucopolysaccharidoses
por: Tomatsu, Shizuka, et al.
Publicado: (2019)

Genome Editing for Mucopolysaccharidoses
por: Poletto, Edina, et al.
Publicado: (2020)

Epidemiology of Mucopolysaccharidoses Update
por: Celik, Betul, et al.
Publicado: (2021)

Bone Biomarkers in Mucopolysaccharidoses
por: Nakamura-Utsunomiya, Akari
Publicado: (2021)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0etl1t9pjrnvh9bjr8g3h5cd11